Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Nutritional Supplements With Specialized Nutrients on Functional Recovery and Morbidity After Gastrointestinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are \> 50 years of age and \< 80 years~2. Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study.~3. Patients who have an ECOG performance status (presurgery) of 0, 1 or 2 (Appendix II).~4. Patients able to orally consume 500 mL or more of liquid a day after adaption~5. Patients undergoing elective gastrointestinal surgery \[e.g. Colorectal surgery: colectomy, hemicolectomy, proctectomy; Small bowel resection/surgery; liver resection, splenectomy, non-whipple pancreatic surgery\]~Exclusion Criteria:~1. Patients who are \> 80 years of age and \< 50 years~2. Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult;~3. Patients undergoing Whipple´s procedure, gastrectomy, oesophageal resection~4. Patients who get preoperative nutritional support~5. Patients taking supplements (EPA, DHA)~6. Any concomitant severe disease e.g.~   * Patients with respiratory failure (FEV\<0.8l/sec)~  * Patients with renal failure (Cr \> 3mg/dl or dialysis patients)~  * Patients with hepatic dysfunction (Child \>A)~  * Patients with cardiac failure (NYHA \> III)~7. Patients suffering from an intestinal obstruction or ileus~8. Patients with an Hb level of \>8 g/dL experiencing gastrointestinal haemorrhaging~9. Patients with HIV~10. Patients requiring immunosuppression treatments~11. Pregnancy~12. Patients undergoing emergency surgery~13. Other patients determined by a study investigator to be inappropriate for enrolment in this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Resource Support® Novartis
- 2 (Type: ACTIVE_COMPARATOR): Resource Protein®, Novartis
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).